GLP-1 agonists, which are relatively new agents in the treatment of type 2 diabetes, possess several benefits over other therapies including less risk for hypoglycemia, modulation of satiety with less weight gain, and preservation of beta cell mass [6]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.